AWA
ABUS icon

Arete Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

Arete Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$46K – 708
2024
Q2 		$46K Buy
+15,000
New +$45K ﹤0.01% 707
2024
Q1 		– Sell
-15,000
Closed -$37.5K – 379
2023
Q4 		$37.5K Hold
15,000
– – ﹤0.01% 722
2023
Q3 		$30.4K Hold
15,000
– – 0.01% 488
2023
Q2 		$35K Hold
15,000
– – ﹤0.01% 650
2023
Q1 		$45K Buy
+15,000
New +$42.3K ﹤0.01% 622
2022
Q4 		– Sell
-15,000
Closed -$29K – 634
2022
Q3 		$29K Buy
+15,000
New +$35.3K ﹤0.01% 564
2022
Q2 		– Sell
-15,000
Closed -$45K – 453
2022
Q1 		$45K Hold
15,000
– – ﹤0.01% 500
2021
Q4 		$58K Buy
+15,000
New +$58.3K ﹤0.01% 494

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return